UPPSALA SCIENCE PARK, Sweden, Dec. 2, 2002 (PRIMEZONE) -- Gyros AB today announced the appointment of Dr. Winfried Girg as Sales Manager for the Company's new Munich-based subsidiary. This local sales organization will support clients based in Germany and Austria and is the next step in the Company's expansion throughout Europe.
Dr. Girg comes from a highly successful career in sales and marketing within Biacore AB, a leading supplier to medical and life science laboratories.
"The German-speaking region represents one of the largest life science markets in Europe," explained Per Sjoberg, Executive Vice President Commercial Operations at Gyros AB. "Dr. Girg's experience and detailed knowledge of this area will be invaluable for a successful introduction of our products and technology platform into this market. Gyros has subsidiaries in the U.K. and the USA and we recently announced agreements with well-established distributors in BeNeLux and Switzerland. Together with our coverage of these other key regions, we are now well-prepared for continued development and expansion of our product portfolio."
Dr. Girg can be contacted at Gyros DE GmbH, Terminalstr. Mitte 18, 85356 Munchen, Deutschland, Tel.: 0049(0)89-97007-266, Fax: 0049(0)89-97007- 200.
About Gyros AB
Gyros miniaturizes and integrates laboratory applications, enabling scientists to generate more information from less sample and to improve lab performance. Using our proprietary technology platform, we increase productivity by streamlining the many steps of conventional applications into single, nanoliter scale procedures. Optimal environments are created for each application. A Gyrolab microlaboratory, in the form of a compact disk, can process hundreds of samples in parallel, under the control of Gyrolab Workstation. Our company will realize the full potential of the Gyros technology platform in the fields of drug discovery and diagnostics. Initial product offerings are focused towards the growing area of proteomics. Gyros has more than 90 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.
For further information, visit www.gyros.com or contact:
Maris Hartmanis, President and CEO Gyros AB Tel: +46 (0)18 566 330 Mobile: +46 (0)70 562 8617 Email: maris.hartmanis@gyros.com Per Sjoberg, Executive Vice President Commercial Operations Gyros AB Tel: +46 (0)18 566 318 Mobile: +46 (0)70 544 4799 Email: per.sjoberg@gyros.com Sue Cresswell, Marketing Communications Tel: +46 (0)8 54472620 Mobile: +46 (0)70 551 9520 Email: sue.cresswell@gyros.com
Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.
Gyros, Gyrolab and the Gyros logo are registered trademarks of Gyros AB.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2002/12/02/20021127BIT00340/wkr0001.doc www.waymaker.net/bitonline/2002/12/02/20021127BIT00340/wkr0002.pdf